申请人:Boehringer Ingelheim International GmbH
公开号:US08975277B2
公开(公告)日:2015-03-10
The present invention relates to compounds of general formula I,
wherein the groups R1, LQ and Ar are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.
本发明涉及一般式I的化合物,其中R1、LQ和Ar基团如本申请所定义,具有有价值的药理特性,特别是能够与GPR119受体结合并调节其活性。